Who are Cladribine Pill's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gemzar, Cladribine Tablets, Gemcitabine Injectable Product, Gemcitabine monotherapy, Gemcitabine Hydrochloride Injection, Cladribine (CLAD).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cladribine-pill.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Cladribine Pill — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cladribine Pill (Cladribine Pill) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Purine nucleoside analog. Area: Immunology; Oncology.

phase 3 Purine nucleoside analog Ribonucleotide reductase; DNA incorporation Immunology; Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Cladribine Pill (Cladribine Pill) — Haukeland University Hospital. Cladribine is a purine nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, leading to selective depletion of lymphocytes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cladribine Pill TARGET	Cladribine Pill	Haukeland University Hospital	phase 3	Purine nucleoside analog	Ribonucleotide reductase; DNA incorporation
Gemzar	Gemcitabine Hydrochloride	Accord Hlthcare	marketed	Nucleoside metabolic inhibitor	Ribonucleotide reductase; DNA incorporation	1996-01-01
Cladribine Tablets	Cladribine Tablets	Keith Edwards, M.D.	marketed	Purine nucleoside analog	Ribonucleotide reductase; DNA incorporation
Gemcitabine Injectable Product	Gemcitabine Injectable Product	Henan Cancer Hospital	marketed	Nucleoside analog antimetabolite	Ribonucleotide reductase; DNA incorporation
Gemcitabine monotherapy	Gemcitabine monotherapy	AstraZeneca	phase 3	Nucleoside analog; antimetabolite	Ribonucleotide reductase; DNA incorporation
Gemcitabine Hydrochloride Injection	Gemcitabine Hydrochloride Injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Nucleoside analog; antimetabolite	Ribonucleotide reductase; DNA incorporation
Cladribine (CLAD)	Cladribine (CLAD)	M.D. Anderson Cancer Center	marketed	Purine nucleoside analog	DNA (via deoxyadenosine analog incorporation)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2030-06-28 — Gemzar · 12403086 · Formulation · US
2032-04-15 — Gemzar · 8679094 · Formulation · US
2033-07-01 — Gemzar · 9241948 · Formulation · US
2034-08-19 — Gemzar · 10729823 · Formulation · US
2034-08-19 — Gemzar · 12447241 · Formulation · US

Sponsor landscape (Purine nucleoside analog class)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · 2 drugs in this class
Haukeland University Hospital · 1 drug in this class
Keith Edwards, M.D. · 1 drug in this class
M.D. Anderson Cancer Center · 1 drug in this class
Nanfang Hospital, Southern Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cladribine Pill — Competitive Intelligence Brief. https://druglandscape.com/ci/cladribine-pill. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing